Unfortunately, there is a lack of conclusive evidence of the value of PSA screening in the reduction of mortality; two randomized controlled PSA screening trials, one in Europe and the other in the US, recently reported disparate results for the effect of PSA testing on prostate cancer mortality [2,3]. This evidence concerns the gene KLK3 and Familial prostate cancer.